IP Library › Granted Patent US 12,570,757
Granted Patent B2
US 12,570,757 · App. 17/764,373 · Granted Mar 10, 2026

Antibodies against the poliovirus receptor (PVR) and uses thereof

Inventors: Philipp Alberts (Amsterdam, NL); Arif Jetha (Toronto, CA); Johan Fransson (San Diego, CA); Yazen Jmeian (New Haven, CT); Joanne Hulme (Toronto, CA); Pinchas Tsukerman (Jerusalem, IL)
Assignee: NECTIN THERAPEUTICS LTD.
C07K16/2896A61P31/14A61P35/02A61P37/02A61K2039/505C07K2317/24C07K2317/30C07K2317/565C07K2317/622C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,570,757
App. No.
17/764,373
Granted
Mar 10, 2026
Kind
B2
Abstract

The present invention provides humanized antibodies and antigen binding fragments thereof that bind to human poliovirus (PVR). The antibodies are useful in the treatment of tumors or cancers.

Claims (19)

1 . A humanized antibody or antigen binding fragment thereof comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence identical to a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, and wherein the light chain variable region comprises an amino acid sequence identical to a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9.

2 . The humanized antibody or antigen binding fragment thereof of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 1, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:2.

3 . The humanized antibody or antigen binding fragment thereof of claim 1 , wherein the humanized antibody or antigen binding fragment thereof is an IgG antibody.

4 . The humanized antibody or antigen binding fragment thereof of claim 3 , wherein the humanized antibody or antigen binding fragment thereof comprises an IgG4 or IgG1 heavy chain constant region.

5 . The humanized antibody or antigen binding fragment thereof according to claim 4 , wherein the humanized antibody or antigen binding fragment thereof comprises an IgG4 heavy chain constant region having an alteration of a serine residue substituted for proline at position 228 of said IgG4 heavy chain constant region, wherein the positions are numbered according to Kabat.

6 . The humanized antibody or antigen binding fragment thereof of claim 1 , wherein the humanized antibody or antigen binding fragment thereof is a Fab, F(ab) 2 , a single-domain antibody, or a single chain variable fragment (scFv).

7 . A single chain variable fragment (scFv) of the humanized antibody according to claim 1 , comprising an amino acid sequence selected from SEQ ID NO: 56 and SEQ ID NO: 57.

8 . The humanized antibody or antigen binding fragment thereof of claim 1 , wherein the humanized antibody inhibits binding of PVR to at least one of TIGIT, CD96, and CD226.

9 . A nucleic acid or nucleic acids encoding at least one chain or region of the humanized antibody or antigen binding fragment thereof of claim 1 .

10 . A cell line comprising the nucleic acid or nucleic acids of claim 9 .

11 . A chimeric antigen receptor (CAR) comprising a combination of heavy and light chain variable region sequences of the humanized antibody according to claim 1 .

12 . A pharmaceutical composition comprising the humanized antibody or antigen binding fragment thereof of claim 1 , and a pharmaceutically acceptable excipient, carrier, or diluent.

13 . A method of increasing surface expression and/or signaling of CD226 in the CD8+ T or NK cells of an individual comprising administering to the individual a therapeutically effective amount of the humanized antibody or antigen binding fragment thereof of claim 1 .

14 . A method of treating a cancer in an individual afflicted with a cancer comprising administering to the individual a therapeutically effective amount of the humanized antibody or antigen binding fragment thereof of claim 1 .

15 . A method of treating a cancer in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of the CAR of claim 11 .

16 . A method of treating a cancer in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of the scFv of claim 7 .

17 . A pharmaceutical composition comprising the scFv of claim 7 , and a pharmaceutically acceptable excipient, carrier, or diluent.

18 . A pharmaceutical composition comprising the CAR of claim 11 , and a pharmaceutically acceptable excipient, carrier, or diluent.

19 . A population of T-cells or NK-cells comprising the CAR of claim 11 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2022
From: ALBERTS, PHILIPP; JETHA, ARIF; FRANSSON, JOHAN; JMEIAN, YAZEN; HULME, JOANNE; TSUKERMAN, PINCHAS
To: NECTIN THERAPEUTICS LTD.
Reel/Frame 059413/0330 →
Continuity (2)
Provisional Application 62912534 · Oct 8, 2019
Related Publication 20220372161A1 · Nov 24, 2022
References Cited (203)
US 3791932A · Schuurs · 1974 [cited by applicant]
US 3839153A · Schuurs · 1974 [cited by applicant]
US 3850578A · McConnell · 1974 [cited by applicant]
US 3850752A · Schuurs · 1974 [cited by applicant]
US 3853987A · Dreyer · 1974 [cited by applicant]
US 3867517A · Ling · 1975 [cited by applicant]
US 3879262A · Schuurs · 1975 [cited by applicant]
US 3901654A · Gross · 1975 [cited by applicant]
US 3935074A · Rubenstein · 1976 [cited by applicant]
US 3984533A · Uzgiris · 1976 [cited by applicant]
US 3996345A · Ullman · 1976 [cited by applicant]
US 4034074A · Miles · 1977 [cited by applicant]
US 4036945A · Haber · 1977 [cited by applicant]
US 4098876A · Piasio · 1978 [cited by applicant]
US 4331647A · Goldenberg · 1982 [cited by applicant]
US 4666828A · Gusella · 1987 [cited by applicant]
US 4683202A · Mullis · 1987 [cited by applicant]
US 4801531A · Frossard · 1989 [cited by applicant]
US 4816567A · Cabilly · 1989 [cited by applicant]
US 4879219A · Wands · 1989 [cited by applicant]
US 4946778A · Ladner · 1990 [cited by applicant]
US 5011771A · Bellet · 1991 [cited by applicant]
US 5192659A · Simons · 1993 [cited by applicant]
US 5225539A · Winter · 1993 [cited by applicant]
US 5272057A · Smulson · 1993 [cited by applicant]
US 5281521A · Trojanowski · 1994 [cited by applicant]
US 5500362A · Robinson · 1996 [cited by applicant]
US 5530101A · Queen · 1996 [cited by applicant]
US 5545806A · Lonberg · 1996 [cited by applicant]
US 5545807A · Surani · 1996 [cited by applicant]
US 5569825A · Lonberg · 1996 [cited by applicant]
US 5585089A · Queen · 1996 [cited by applicant]
US 5624821A · Winter · 1997 [cited by applicant]
US 5625126A · Lonberg · 1997 [cited by applicant]
US 5633425A · Lonberg · 1997 [cited by applicant]
US 5641870A · Rinderknecht · 1997 [cited by applicant]
US 5648260A · Winter · 1997 [cited by applicant]
US 5661016A · Lonberg · 1997 [cited by applicant]
US 5693761A · Queen · 1997 [cited by applicant]
US 5693762A · Queen · 1997 [cited by applicant]
US 5821337A · Carter · 1998 [cited by applicant]
US 6518033B1 · Gromeier · 2003 [cited by applicant]
US 7045605B2 · Bander · 2006 [cited by applicant]
US 7244429B2 · Zhou · 2007 [cited by applicant]
US 7365167B2 · Watkins · 2008 [cited by applicant]
US 7371826B2 · Presta · 2008 [cited by applicant]
US 7709610B2 · Williams · 2010 [cited by applicant]
US 7744874B2 · Korytko · 2010 [cited by applicant]
US 7785593B2 · Barske · 2010 [cited by applicant]
US 8637643B2 · Latham · 2014 [cited by applicant]
US 8652469B2 · Kavanaugh · 2014 [cited by applicant]
US 8841418B2 · Karsunky · 2014 [cited by applicant]
US 20050014934A1 · Hinton · 2005 [cited by applicant]
US 20050153447A1 · Berenson · 2005 [cited by applicant]
US 20070041985A1 · Unger · 2007 [cited by applicant]
US 20080019974A1 · Kim · 2008 [cited by applicant]
US 20090215175A1 · Unger · 2009 [cited by applicant]
US 20090258013A1 · Clark · 2009 [cited by applicant]
US 20090280128A1 · Kamogawa · 2009 [cited by applicant]
US 20130095116A1 · Gurney · 2013 [cited by applicant]
US 20140056890A1 · Gurney · 2014 [cited by applicant]
US 20140186380A1 · Gurney · 2014 [cited by applicant]
US 20140302034A1 · Bankovich · 2014 [cited by applicant]
US 20150216970A1 · Grogan · 2015 [cited by applicant]
US 20170037133A1 · Fiedler · 2017 [cited by applicant]
CN 109071666A · 2018 [cited by applicant]
CN 110256558A · 2019 [cited by applicant]
EP 0404097A2 · 1990 [cited by applicant]
EP 1481993A1 · 2004 [cited by applicant]
JP 2011153992A · 2011 [cited by applicant]
JP 2014198710A · 2014 [cited by applicant]
JP 2015134764A · 2015 [cited by applicant]
JP 2018531914A · 2018 [cited by applicant]
RU 2451689C2 · 2012 [cited by applicant]
WO 8601533A1 · 1986 [cited by applicant]
WO 9007861A1 · 1990 [cited by applicant]
WO 9222653A1 · 1992 [cited by applicant]
WO 9311161A1 · 1993 [cited by applicant]
WO 9315210A1 · 1993 [cited by applicant]
WO 9402610A1 · 1994 [cited by applicant]
WO 9429351A2 · 1994 [cited by applicant]
WO 9503832A1 · 1995 [cited by applicant]
WO 9613583A2 · 1996 [cited by applicant]
WO 9637621A2 · 1996 [cited by applicant]
WO 0008166A1 · 2000 [cited by applicant]
WO 03080672A1 · 2003 [cited by applicant]
WO 2004074324A2 · 2004 [cited by applicant]
WO 2006124667A2 · 2006 [cited by applicant]
WO 2007072866A1 · 2007 [cited by applicant]
WO 2014130879A2 · 2014 [cited by applicant]
WO 2015009856A2 · 2015 [cited by applicant]
WO 2015031693A1 · 2015 [cited by applicant]
WO 2015051159A1 · 2015 [cited by applicant]
WO 2015142303A1 · 2015 [cited by applicant]
WO 2017021526A1 · 2017 [cited by applicant]
WO 2017149538A1 · 2017 [cited by applicant]
Caldas et al. Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen. Molecular Immunology 39 (2003) 941-952 (Year: 2003). [cited by examiner]
Tamura et al., (2000) Structural correlates of an anticarcinoma antibody: identification of specificity-determining 1 residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only… [cited by applicant]
Al-Lazikani et al., (1997) Standard conformations for the canonical structures of immunoglobulins. J Mol Biol 273(4): 927-948. [cited by applicant]
Altschul et al., (1990) Basic local alignment search tool. J Mol Biol 215(3): 403-410. [cited by applicant]
Beerli et al., (1994) Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J Biol Chem 269 (39): 23931-23936. [cited by applicant]
Berman and Henson (2003) Classifying the precancers: a metadata approach. BMC Med Inform Decis Mak 3: 8; 9 pages. [cited by applicant]
Biocca et al., (1994) Intracellular immunization with cytosolic recombinant antibodies. Biotechnology (N Y) 12(4): 396-399. [cited by applicant]
Bird et al., (1988) Single-chain antigen-binding proteins. Science 242(4877): 423-426. [cited by applicant]
Blake et al., (2016) Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy. Cancer Discov 6(4): 446-459. [cited by applicant]
Boerner et al., (1991) Production of antigen-specific human monoclonal antibodies from in vitro-primed human splenocytes. J Immunol 147(1): 86-95. [cited by applicant]
Bottino et al., (2003) Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 198(4): 557-567. [cited by applicant]
Brennan et al., (1985) Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science 229(4708): 81-83. [cited by applicant]
Bryson et al., (2010) Prediction of immunogenicity of therapeutic proteins: validity of computational tools. BioDrugs 24 (1): 1-8. [cited by applicant]
Carlson (1993) A new use for intracellular antibody expression: inactivation of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 90(16): 7427-7428. [cited by applicant]
Carter et al., (1992) High level [cited by applicant]
Chauvin et al., (2015) TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. J Clin Invest 125(5): 2046-2058. [cited by applicant]
Chen et al., (1994) Intracellular antibodies as a new class of therapeutic molecules for gene therapy. Hum Gene Ther 5(5): 595-601. [cited by applicant]
Chen et al., (1994) Combined intra- and extracellular immunization against human immunodeficiency virus type 1 infection with a human anti-gp120 antibody. Proc Natl Acad Sci U S A 91(13): 5932-5936. [cited by applicant]
Chothia et al., (1989) Conformations of immunoglobulin hypervariable regions. Nature 342(6252): 877-883. [cited by applicant]
Chowdhury (2003) Engineering hot spots for affinity enhancement of antibodies. Methods Mol Biol 207: 179-196. [cited by applicant]
Clackson et al., (1991) Making antibody fragments using phage display libraries. Nature 352(6336): 624-628. [cited by applicant]
Colman (1994) Effects of amino acid sequence changes on antibody-antigen interactions. Res Immunol 145(1): 33-36. [cited by applicant]
Cunningham and Wells (1989) High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science 244(4908): 1081-1085. [cited by applicant]
Deng Huping (2007); “The mechanism of soluble CD155 production”. Master's thesis. Department of Immunology, The Fourth Military Medical University, Xi'an, China. total 82 pages including English abstract appear on pp. 7… [cited by applicant]
Deshane et al., (1994) Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Gene Ther… [cited by applicant]
Duan et al., (1994) Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody. Proc Natl Acad Sci U S A 91(11): 5075-5079 with retraction and corrections. [cited by applicant]
Duncan and Winter (1988) The binding site for C1q on IgG. Nature 332(6166): 738-740. [cited by applicant]
Fields et al., (2013) Creation of recombinant antigen-binding molecules derived from hybridomas secreting specific antibodies. Nat Protoc 8(6): 1125-1148. [cited by applicant]
Fishwild et al., (1996) High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol 14(7): 845-851. [cited by applicant]
Fuchs et al., (2004) Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155). J Immunol 172(7): 3994-3998. [cited by applicant]
Gilfillan et al., (2008) DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med 205(13): 2965-2973. [cited by applicant]
Gupta et al., (2015) PEITC treatment suppresses myeloid derived tumor suppressor cells to inhibit breast tumor growth. Oncoimmunology 4(2): e981449; 9 pages. [cited by applicant]
Holliger et al., (1993) “Diabodies”: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A 90(14): 6444-6448. [cited by applicant]
Honegger and Pluckthun (2001) Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool. J Mol Biol 309(3): 657-670. [cited by applicant]
Hoogenboom and Winter (1992) By-passing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro. J Mol Biol 227(2): 381-388. [cited by applicant]
Huntress Rick; Patient-derived tumor xenografts in humanized NSGTM mice: a model to study immune responses in cancer therapy. The Jackson Laboratory. Retrieved from: http://immune-checkpoint.com/wp-content/uploads/sites… [cited by applicant]
Huston et al., (1988) Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in [cited by applicant]
Inbar et al., (1972) Localization of antibody-combining sites within the variable portions of heavy and light chains. Proc Natl Acad Sci U S A 69(9): 2659-2662. [cited by applicant]
Inozume et al., (2013) Development of a novel immunotherapy for melanoma which inhibits interaction between CD155 on melanoma cells and TIGIT on activated CTL. Journal of Investigative Dermatology 133(suppl 1): S3. Abst… [cited by applicant]
Johnston et al., (2014) The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 26(6): 923-937. [cited by applicant]
Jones et al., (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321(6069): 522-525. [cited by applicant]
Kakunaga et al., (2004) Enhancement of serum- and platelet-derived growth factor-induced cell proliferation by Necl-5/Tage4/poliovirus receptor/CD155 through the Ras-Raf-MEK-ERK signaling. J Biol Chem 279(35): 36419-364… [cited by applicant]
Karlin and Altschul (1990) Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes. Proc Natl Acad Sci U S A 87(6): 2264-2268. [cited by applicant]
Karlin and Altschul (1993) Applications and statistics for multiple high-scoring segments in molecular sequences. Proc Natl Acad Sci U S A 90(12): 5873-5877. [cited by applicant]
Kinugasa et al., (2012) Necl-5/poliovirus receptor interacts with VEGFR2 and regulates VEGF-induced angiogenesis. Circ Res 110(5): 716-726. [cited by applicant]
Köhler and Milstein (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 (5517): 495-497. [cited by applicant]
Kučan Brlić et al., (2019) Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cell Mol Immunol 16(1): 40-52. [cited by applicant]
Larrick and Fry (1991) PCR amplification of antibody genes. Methods 2(2): 106-110. [cited by applicant]
Lee et al., (2014) Inhibition of breast cancer growth and metastasis by a biomimetic peptide. Sci Rep 4: 7139; 12 pages. [cited by applicant]
Lee et al., (2020) Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade. JCI Insight 5(14): e128633; 16 pages. [cited by applicant]
Lefranc et al., (2003) IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. Dev Comp Immunol 27(1): 55-77. [cited by applicant]
Li et al., (2010) Cell culture processes for monoclonal antibody production. MAbs 2(5): 466-479. [cited by applicant]
Li et al., (2018) CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. J Clin Invest 128(6): 2613-2625. [cited by applicant]
Liu et al., (2015) Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. Cancer Res 75(17): 3596-3607. [cited by applicant]
Lonberg and Huszar (1995) Human antibodies from transgenic mice. Int Rev Immunol 13(1): 65-93. [cited by applicant]
Lonberg et al., (1994) Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368(6474): 856-859. [cited by applicant]
MacCallum et al., (1996) Antibody-antigen interactions: contact analysis and binding site topography. J Mol Biol 262(5): 732-745. [cited by applicant]
Makabe et al., (2008) Thermodynamic consequences of mutations in vernier zone residues of a humanized anti-human epidermal growth factor receptor murine antibody, 528. J Biol Chem 283(2): 1156-1166. [cited by applicant]
Marasco et al., (1998) Intracellular antibodies against HIV-1 envelope protein for AIDS gene therapy. Hum Gene Ther 9(11): 1627-1642. [cited by applicant]
Mariuzza et al., (1987) The structural basis of antigen-antibody recognition. Annu Rev Biophys Biophys Chem 16: 139-159. [cited by applicant]
Marks et al., (1991) By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 222(3): 581-597. [cited by applicant]
Marks et al., (1992) By-passing immunization: building high affinity human antibodies by chain shuffling. Biotechnology (N Y) 10(7): 779-783. [cited by applicant]
Martin et al., (1989) Modeling antibody hypervariable loops: a combined algorithm. Proc Natl Acad Sci U S A 86(23): 9268-9272. [cited by applicant]
Meuer et al., (1984) An alternative pathway of T-cell activation: a functional role for the 50 kd T11 sheep erythrocyte receptor protein. Cell 36(4): 897-906. [cited by applicant]
Mhashilkar et al., (1995) Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. EMBO J 14(7): 1542-1551. [cited by applicant]
Morimoto and Inouye (1992) Single-step purification of F(ab′)2 fragments of mouse monoclonal antibodies (immunoglobulins G1) by hydrophobic interaction high performance liquid chromatography using TSKgel Phenyl-5PW. J B… [cited by applicant]
Morimoto et al., (2008) Interaction of cancer cells with platelets mediated by Necl-5/poliovirus receptor enhances cancer cell metastasis to the lungs. Oncogene 27(3): 264-273. [cited by applicant]
Morrison (1994) Immunology. Success in specification. Nature 368(6474): 812-813. [cited by applicant]
Morrison et al., (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A 81(21): 6851-6855. [cited by applicant]
Nelson et al., (2000) Demystified . . . Monoclonal antibodies. Mol Pathol 53(3): 111-117. [cited by applicant]
Neuberger (1996) Generating high-avidity human Mabs in mice. Nat Biotechnol 14(7): 826. [cited by applicant]
Nishiwada et al., (2015) Clinical significance of CD155 expression in human pancreatic cancer. Anticancer Res 35(4): 2287-2297 with correction. [cited by applicant]
Pack et al., (1993) Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of [cited by applicant]
Perry et al., (2008) New approaches to prediction of immune responses to therapeutic proteins during preclinical development. Drugs R D 9(6): 385-396. [cited by applicant]
Podsypanina et al., (2008) Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras. Proc Natl Acad Sci U S A 105(13): 5242-5247. [cited by applicant]
Porter (1959) The hydrolysis of rabbit y-globulin and antibodies with crystalline papain. Biochem J 73(1): 119-126. [cited by applicant]
Portolano et al., (1993) Lack of promiscuity in autoantigen-specific H and L chain combinations as revealed by human H and L chain “roulette”. J Immunol 150(3): 880-887. [cited by applicant]
Presta (1992) Antibody engineering. Current Opinion in Structural Biology 2(4): 593-596. [cited by applicant]
Refaeli et al., (2005) The protooncogene MYC can break B cell tolerance. Proc Natl Acad Sci U S A 102(11): 4097-4102. [cited by applicant]
Refaeli et al., (2008) The B cell antigen receptor and overexpression of MYC can cooperate in the genesis of B cell lymphomas. PLoS Biol 6(6): 1208-1225. [cited by applicant]
Richardson and Marasco (1995) Intracellular antibodies: development and therapeutic potential. Trends Biotechnol 13(8): 306-310. [cited by applicant]
Richardson et al., (1995) Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha subunit of the receptor. Proc Natl Acad Sci U S A 92(8): 3137-31… [cited by applicant]
Riechmann et al., (1988) Reshaping human antibodies for therapy. Nature 332(6162): 323-327. [cited by applicant]
Roh et al., (2006) Transgenic mice for Cre-inducible overexpression of the oncogenes c-MYC and Pim-1 in multiple tissues. Genesis 44(10): 447-453. [cited by applicant]
Rudikoff et al., (1982) Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci U S A 79(6): 1979-1983. [cited by applicant]
Sakahara et al., (1985) Effect of DTPA conjugation on the antigen binding activity and biodistribution of monoclonal antibodies against alpha-fetoprotein. J Nucl Med 26(7): 750-755. [cited by applicant]
Scarano et al., (2010) Surface plasmon resonance imaging for affinity-based biosensors. Biosens Bioelectron 25(5): 957-966. [cited by applicant]
Schmidt et al., (1988) Transgenic mice bearing the human c-myc gene activated by an immunoglobulin enhancer: a pre-B-cell lymphoma model. Proc Natl Acad Sci U S A 85(16): 6047-6051. [cited by applicant]
Shaheen et al., (1996) Targeting human immunodeficiency virus type 1 reverse transcriptase by intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle J Virol 70(6): 33… [cited by applicant]
Shibuya et al., (1996) DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 4(6): 573-581. [cited by applicant]
Shibuya et al., (1999) Physical and functional association of LFA-1 with DNAM-1 adhesion molecule. Immunity 11(5): 615-623. [cited by applicant]
Solecki et al., (2002) Expression of the human poliovirus receptor/CD155 gene is activated by sonic hedgehog. J Biol Chem 277(28): 25697-25702. [cited by applicant]
Stanietsky et al., (2009) The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A 106(42): 17858-17863. [cited by applicant]
Stanietsky et al., (2013) Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR. Eur J Immunol 43(8): 2138-2150. [cited by applicant]
Topalian et al., (2015) Immunotherapy: The path to win the war on cancer?. Cell 161(2): 185-186. [cited by applicant]
Verhoeyen et al., (1988) Reshaping human antibodies: grafting an antilysozyme activity. Science 239(4847): 1534-1536. [cited by applicant]
Wang et al., (2019) Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells. Cytotherapy 21(5): 566-578. [cited by applicant]
Ward et al., (1989) Binding activities of a repertoire of single immunoglobulin variable domains secreted from [cited by applicant]
Werge et al., (1990) Intracellular immunization. Cloning and intracellular expression of a monoclonal antibody to the p21ras protein. FEBS Lett 274(1-2): 193-198. [cited by applicant]
Whitelegg and Rees (2000) WAM: an improved algorithm for modelling antibodies on the WEB. Protein Eng 13(12): 819-824. [cited by applicant]
Whitlow and Filpula (1991) Single-chain Fv proteins and their fusion proteins. Methods 2(2): 97-105. [cited by applicant]
Wu and Kabat (1970) An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. J Exp Med 132(2): 211-250. [cited by applicant]
Yang et al., (1986) A common pathway for T lymphocyte activation involving both the CD3-Ti complex and CD2 sheep erythrocyte receptor determinants. J Immunol 137(4): 1097-1100. (Abstract only, 1 page). [cited by applicant]
Yu et al., (2009) The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol 10(1): 48-57. [cited by applicant]
Zapata et al., (1995) Engineering linear F(ab′)2 fragments for efficient production in [cited by applicant]
Zhang Qing et al., (2015) “Anti-tumor immunotherapy and effect mechanism of TIGIT blocking monoclonal antibody”. Institute of Immunology, School of Life Sciences, University of Science and Technology of China. with Mach… [cited by applicant]
Zhu et al., (2016) Identification of CD112R as a novel checkpoint for human T cells. J Exp Med 213(2): 167-176. [cited by applicant]